Newer medications that are particularly promising for the treatment of diabetic nephropathy in the future include CCL2 and CCR2 inhibitors as well as anti-oxidative stress therapies such as NOX inhibitors.
There are several experimental therapies for diabetic nephropathy (DN) that are currently being tested. These include the use of existing medications such as pentoxifylline, allopurinol, SGLT2 inhibitors and GLP-1 agonists, and assessing their application in DN. Further newer medications that are particularly promising include CCL2 and CCR2 inhibitors as well as anti-oxidative stress therapies such as NOX inhibitors. With knowledge of the pathogenesis of DN expanding, new potential therapeutic targets are being discovered. Many of these are still in an early clinical trials stage, but results are promising. It is likely that within the next decade some of these will be available for clinical use; potentially providing new therapeutic options for the many patients who are affected by this devastating diabetic complication.